| P50 | author | David S Goldstein | Q48111809 |
| P2093 | author name string | Irwin J Kopin | |
| P2860 | cites work | Proteome analysis of human substantia nigra in Parkinson's disease | Q21245637 |
| | Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease | Q24632904 |
| | Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal | Q48427935 |
| | Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilization stress in rats: an in vivo microdialysis study | Q48443752 |
| | Stressor-specific activation of catecholaminergic systems: implications for stress-related hypothalamic-pituitary-adrenocortical responses. | Q48609328 |
| | Heterogeneous neurochemical responses to different stressors: a test of Selye's doctrine of nonspecificity. | Q48713323 |
| | A syndrome produced by diverse nocuous agents. 1936. | Q48805633 |
| | Effects of handling or immobilization on plasma levels of 3,4-dihydroxyphenylalanine, catecholamines, and metabolites in rats | Q48837239 |
| | Tetrahydropapaveroline: an alkaloid metabolite of dopamine in vitro | Q48901203 |
| | Dopamine efflux from striatal slices after intracerebral 6-hydroxydopamine: evidence for compensatory hyperactivity of residual terminals | Q49013086 |
| | Stressor specificity of peripheral catecholaminergic activation. | Q51535183 |
| | Adrenalectomy augments in vivo release of norepinephrine in the paraventricular nucleus during immobilization stress. | Q52033557 |
| | 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. | Q52579869 |
| | Effect of handling and forced immobilization on rat plasma levels of epinephrine, norepinephrine, and dopamine-beta-hydroxylase | Q52963689 |
| | Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alpha-synuclein. | Q53285842 |
| | Pleiotropy, Natural Selection, and the Evolution of Senescence | Q54299553 |
| | A Syndrome produced by Diverse Nocuous Agents | Q56835784 |
| | Plasma dopa responses during stress: dependence on sympathoneural activity and tyrosine hydroxylation | Q68148778 |
| | Divergent changes in D-1 and D-2 dopamine binding sites in human brain during aging | Q69079990 |
| | Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats | Q70473320 |
| | Adrenal and Urinary Catecholamines in Rats During Adaptation to Repeated Immobilization Stress | Q71527074 |
| | Enhanced synthesis of adrenal dopamine beta-hydroxylase induced by repeated immobilization in rats | Q71777292 |
| | Synthesis of Adrenal Catecholamines in Rats During and After Immobilization Stress | Q71841580 |
| | Age-related thermoregulatory differences during core cooling in humans | Q74008512 |
| | Alpha-synuclein overexpression increases cytosolic catecholamine concentration | Q80223133 |
| | Effects of 6-hydroxydopamine on the activity of tyrosine hydroxylase and dopamine- -hydroxylase in sympathetic ganglia of the rat | Q93708787 |
| | Elevation of Adrenal Tyrosine Hydroxylase and Phenylethanolamine-N-Methyl Transferase by Repeated Immobilization of Rats | Q43525405 |
| | 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis | Q43725921 |
| | "Structural factor" in primary and secondary hypertension | Q43987755 |
| | 5-s-Cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons | Q44029764 |
| | Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. | Q44264439 |
| | Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension | Q44411550 |
| | 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis | Q44616102 |
| | Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication | Q44737169 |
| | Different effects of novel stressors on sympathoadrenal system activation in rats exposed to long-term immobilization | Q44968443 |
| | Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism | Q46519398 |
| | Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease. | Q47365156 |
| | Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy | Q47772222 |
| | Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. | Q48006941 |
| | Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications | Q48088787 |
| | Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. | Q48257438 |
| | Parkinson disease: Traumatic brain injury increases the risk of Parkinson disease | Q48267189 |
| | Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum | Q48301354 |
| | Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species | Q48362189 |
| | Osmotic regulation of plasma vasopressin and oxytocin after sustained hyponatremia | Q48368742 |
| | Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders | Q26826093 |
| | Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease | Q26850502 |
| | Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 |
| | alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 |
| | Alpha-synuclein in Lewy bodies | Q27860680 |
| | Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration | Q28237641 |
| | Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells | Q28256395 |
| | Brain dopamine-serotonin vesicular transport disease and its treatment | Q28284572 |
| | Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells | Q28286006 |
| | Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata | Q28377237 |
| | Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007 | Q28387116 |
| | Stressor specificity and effect of prior experience on catecholamine biosynthetic enzyme phenylethanolamine N-methyltransferase | Q28576565 |
| | Chronic systemic pesticide exposure reproduces features of Parkinson's disease | Q29614763 |
| | Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons | Q31673344 |
| | Cerebrospinal fluid levels of catechols in patients with neurogenic orthostatic hypotension | Q33148501 |
| | Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine | Q33344779 |
| | Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus | Q33724885 |
| | The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis | Q33778472 |
| | Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis | Q33862898 |
| | Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease | Q33896138 |
| | Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease | Q34181738 |
| | A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitus-syndrome X complex. | Q34193110 |
| | A vesicular sequestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease | Q34560077 |
| | Fate of tritiated noradrenaline at the sympathetic nerve-endings | Q34648890 |
| | In vivo demonstration that alpha-synuclein oligomers are toxic | Q34652122 |
| | Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases | Q35142854 |
| | Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease | Q35181537 |
| | Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism | Q35557892 |
| | Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy | Q35638948 |
| | Traumatic brain injury in later life increases risk for Parkinson disease | Q35661022 |
| | Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons | Q35807528 |
| | Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity | Q35810975 |
| | Evidence that catecholamine transport into chromaffin vesicles is coupled to vesicle membrane potential | Q35996798 |
| | Deficient vesicular storage: A common theme in catecholaminergic neurodegeneration. | Q36011221 |
| | Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease | Q36063269 |
| | Catechols in post-mortem brain of patients with Parkinson disease | Q36086433 |
| | Sympathetic neurocirculatory failure in Parkinson disease: Evidence for an etiologic role of alpha-synuclein | Q36100326 |
| | Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL). | Q36282886 |
| | A physiologist's view of homeostasis | Q36345958 |
| | Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 cells: relevance to the pathogenesis of Parkinson's disease | Q36445937 |
| | Comparison of Monoamine Oxidase Inhibitors in Decreasing Production of the Autotoxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde in PC12 Cells | Q36559682 |
| | Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. | Q36767402 |
| | Chronic restraint stress triggers dopaminergic and noradrenergic neurodegeneration: Possible role of chronic stress in the onset of Parkinson's disease | Q36848200 |
| | Chronic intermittent hypoxia sensitizes acute hypothalamic-pituitary-adrenal stress reactivity and Fos induction in the rat locus coeruleus in response to subsequent immobilization stress | Q36849018 |
| | Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behaviora | Q36969314 |
| | Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases | Q36987273 |
| | Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems | Q36992085 |
| | Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in Mice | Q37334985 |
| | Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons | Q37406074 |
| | Catecholaminergic systems in stress: structural and molecular genetic approaches. | Q37431126 |
| | DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. | Q37584540 |
| | Stress, allostatic load, catecholamines, and other neurotransmitters in neurodegenerative diseases | Q37590347 |
| | Head injury and risk of Parkinson disease: a systematic review and meta-analysis | Q38100976 |
| | Can stress trigger Parkinson's disease? | Q38164648 |
| | Mitochondrial allostatic load puts the 'gluc' back in glucocorticoids. | Q38198954 |
| | Aldehyde dehydrogenase (ALDH) in Alzheimer's and Parkinson's disease | Q38258298 |
| | Determinants of denervation-independent depletion of putamen dopamine in Parkinson's disease and multiple system atrophy. | Q39052138 |
| | Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease? | Q39149230 |
| | Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism | Q39460581 |
| | Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings | Q39613940 |
| | The Uptake, Storage, Release and Metabolism of Noradrenaline in Sympathetic Nerves | Q39984945 |
| | Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels. | Q40047308 |
| | Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. | Q40226743 |
| | Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line | Q40714967 |
| | Selective genetic disruption of dopaminergic, serotonergic and noradrenergic neurotransmission: insights into motor, emotional and addictive behaviour. | Q40879980 |
| | Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde | Q40882148 |
| | Sympathoadrenal system in stress. Interaction with the hypothalamic-pituitary-adrenocortical system | Q40967745 |
| | Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease | Q41775688 |
| | Antioxidant-Mediated Modulation of Protein Reactivity for 3,4-Dihydroxyphenylacetaldehyde, a Toxic Dopamine Metabolite | Q42196555 |
| | Innervation-independent changes in the mRNAs encoding tyrosine hydroxylase and the norepinephrine transporter in rat adrenal medulla after high-dose reserpine | Q42274461 |
| | Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases | Q42438205 |
| | Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse | Q42492845 |
| | Effects of single or repeated immobilization on release of norepinephrine and its metabolites in the central nucleus of the amygdala in conscious rats | Q42506927 |
| | Endogenous catecholamine enhances the dysfunction of unfolded protein response and alpha-synuclein oligomerization in PC12 cells overexpressing human alpha-synuclein | Q43260035 |
| P433 | issue | 1 | |
| P921 | main subject | neurodegeneration | Q1755122 |
| P304 | page(s) | 13-24 | |
| P577 | publication date | 2017-05-09 | |
| P1433 | published in | Cellular and Molecular Neurobiology | Q2333197 |
| P1476 | title | Linking Stress, Catecholamine Autotoxicity, and Allostatic Load with Neurodegenerative Diseases: A Focused Review in Memory of Richard Kvetnansky | |
| P478 | volume | 38 | |